Individual agents, and it is achievable that the patients who failed IM400 when no second-generation inhibitors had been out there, would have been salvaged far more efficiently with dasatinib or nilotinib. In any case the expectation that the cost differential amongst imatinib and secondgeneration TKIs will enhance dramatically with all the availability of generic imatinib in 2015 recommend that imatinib will maintain a considerable part in frontline CML therapy, and our information recommend that higher doses may well grow to be part of the treatment algorithm.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptBr J Haematol. Author manuscript; readily available in PMC 2015 January 01.Deininger et al.PageAcknowledgmentsWe thank Patricia Arlauskas, SWOG Publications Workplace, for editorial help. Grant Support: This investigation was supported in portion by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA35261; CA35431; CA27057; CA13238; CA45807; CA58882; CA67575; CA46113, CA46368, CA12644, CA45808, CA20319, CA35128, CA35176, CA11083, CA76462, CA46282, CA35119, CA04919, CA63848, CA37981, CA16385, CA22433, CA35090, CA31946, CA41287; and in aspect by Bristol-Myers Squibb. Michael W Deininger is a Scholar in Clinical Investigation on the Leukemia Lymphoma Society.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptReference ListBaccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R.Tris(hydroxypropyl)phosphine web Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009a; 27:6041?051. [PubMed: 19884523] Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B.Silver(I) carbonate web Comparison of imatinib 400 mg and 800 mg day-to-day in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.PMID:23865629 Blood. 2009b; 113:4497?504. [PubMed: 19264678] Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G. Results of high-dose imatinib mesylate in intermediate Sokal danger chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood. 2009; 113:3428?434. [PubMed: 19211938] Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase applying molecular finish points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28:424?30. [PubMed: 20008622] Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J. High-dose imatinib in newly di.
